Protocol Ledger

NCT07005154 · Phase II · RECRUITING

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Interventional Phase II clinical trial protocol NCT07005154 sponsored by Astellas Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-19 Enrollment: 218 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07005154
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)218 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07005154
Protocol FieldVerified Registry Value
NCT IdentifierNCT07005154
Consolidated Lead SponsorAstellas Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment218 participants (ESTIMATED)
Registered Start Date2025-08-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07005154
Hospital Research SiteLocationSite Profile
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->
Carolina Urologic Research CenterMyrtle Beach, SCOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI